US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Polyrizon Ltd.

0.3828

+0.02186.04%

Post-market: 0.3637-0.0191-4.99%18:21 EDT

Volume:103.28K

Turnover:38.63K

Market Cap:15.24M

PE:- -

High:0.3900

Open:0.3760

Low:0.3630

Close:0.3610

Loading ...

Overview Company News Filings

Polyrizon Signs Non– Binding LOI to Expand its Innovative Intranasal Drug Delivery Platform for Psychedelic-Based Treatments

BRIEF-Polyrizon launches preclinical studies on intranasal version of treatment to reverse opioid overdoses

Polyrizon Launches Preclinical Studies for Intranasal Naloxone to Combat Opioid Overdose Using Cutting-Edge Platform

THOMSON REUTERS

Polyrizon Launches Preclinical Studies for Intranasal Naloxone to Combat Opioid Overdose Using Cutting-Edge Platform

Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024

Polyrizon Initiates Preclinical Studies for Intranasal Naloxone Targeting Opioid Overdose Based on Its Innovative T&T Platform

Polyrizon files divisional patent application with Israel Patent Office

Polyrizon Announces Filing of Divisional Patent Application for Its Innovative Trap & Target™ (T&T) Intranasal Drug Delivery Platform

BRIEF-Polyrizon Commences Gmp Manufacturing Preliminary Process

Polyrizon Commences Gmp Manufacturing Preliminary Process for Its Pl-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial

THOMSON REUTERS

Polyrizon Commences GMP Manufacturing Preliminary Process for its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial

BRIEF-Polyrizon Ltd Files Prospectus Related To Resale By Selling Shareholders Of Up To 2.4 Million Ordinary Shares - SEC Filing

Polyrizon files to sell 2.42M ordinary shares for holders

Polyrizon Ltd: Files Prospectus Related to Resale by Selling Shareholders of up to 2.4 Mln Ordinary Shares - SEC Filing

THOMSON REUTERS

Polyrizon Shares Rise After Publication of National Patent Application

Risk Aversion Grips Wall Street in Penultimate Session of 2024, Fueling Premarket Losses for US Equity Futures

MT Newswires Live

Polyrizon Files US Patent Application for Nasal Drug Delivery Platforms; Shares Jump Pre-Bell

MT Newswires Live

Top Premarket Gainers

MT Newswires Live

Polyrizon announces publication of patent application for hydrogel nasal tech

Polyrizon appoints Michal Meir as senior director, regulatory & clinical affairs

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/PLRZ/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PLRZ","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PLRZ\",,,,,undefined,":{"symbol":"PLRZ","market":"US","secType":"STK","nameCN":"Polyrizon Ltd.","latestPrice":0.3828,"timestamp":1744401600000,"preClose":0.361,"halted":0,"volume":103277,"hourTrading":{"tag":"盘后","latestPrice":0.3637,"preClose":0.3828,"latestTime":"18:21 EDT","volume":13566,"amount":4934.0007,"timestamp":1744410116721},"delay":0,"floatShares":37529021,"shares":39811100,"eps":0,"marketStatus":"Closed","change":0.0218,"latestTime":"04-11 16:00:00 EDT","open":0.376,"high":0.39,"low":0.363,"amount":38629.50806722,"amplitude":0.074792,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1744617600000},"marketStatusCode":5,"adr":0,"listingDate":1730174400000,"exchange":"NASDAQ","adjPreClose":0.361,"preHourTrading":{"tag":"盘前","latestPrice":0.365,"preClose":0.361,"latestTime":"09:23 EDT","volume":1,"amount":0.365,"timestamp":1744377813594},"postHourTrading":{"tag":"盘后","latestPrice":0.3637,"preClose":0.3828,"latestTime":"18:21 EDT","volume":13566,"amount":4934.0007,"timestamp":1744410116721},"volumeRatio":0.713495},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PLRZ\",,,,,undefined,":{"symbol":"PLRZ","floatShares":37529021,"roa":"-26.65%","roe":"-57.83%","lyrEps":0,"volumeRatio":0.713495,"shares":39811100,"dividePrice":0,"high":0.39,"amplitude":0.074792,"preClose":0.361,"low":0.363,"week52Low":0.2806,"pbRate":"2.88","week52High":4.8,"institutionHeld":0,"latestPrice":0.3828,"eps":0,"divideRate":0,"volume":103277,"delay":0,"ttmEps":0,"open":0.376,"prevYearClose":2.17,"prevWeekClose":0.346,"prevMonthClose":0.369,"prevQuarterClose":0.369,"fiveDayClose":0.346,"twentyDayClose":0.56,"sixtyDayClose":1.395},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PLRZ\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2519098028","title":"Polyrizon Signs Non– Binding LOI to Expand its Innovative Intranasal Drug Delivery Platform for Psychedelic-Based Treatments","url":"https://stock-news.laohu8.com/highlight/detail?id=2519098028","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519098028?lang=en_us&edition=fundamental","pubTime":"2025-03-14 20:35","pubTimestamp":1741955700,"startTime":"0","endTime":"0","summary":"Raanana, Israel, March 14, 2025  -- Polyrizon Ltd.  , a development stage biotech company specializing in the development of innovative intranasal hydrogels, announced today that it has signed a non-binding Letter of Intent  with a biotech company focused on psychedelic-derived therapeutics , to develop a novel intranasal formulation for psychedelic-based treatment applications.Polyrizon is a development stage biotech company specializing in the development of innovative medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Polyrizon’s proprietary Capture and ContainTM, or C&C, hydrogel technology, comprised of a mixture of naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a “biological mask” with a thin shield containment barrier in the na","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/polyrizon-signs-non-binding-loi-123500371.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PLRZ"],"gpt_icon":0},{"id":"2519835468","title":"BRIEF-Polyrizon launches preclinical studies on intranasal version of treatment to reverse opioid overdoses","url":"https://stock-news.laohu8.com/highlight/detail?id=2519835468","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519835468?lang=en_us&edition=fundamental","pubTime":"2025-03-13 20:10","pubTimestamp":1741867854,"startTime":"0","endTime":"0","summary":"BRIEF-Polyrizon launches preclinical studies on intranasal version of treatment to reverse opioid overdosesMarch 13 (Reuters) - Polyrizon Ltd PLRZ.O:POLYRIZON LAUNCHES PRECLINICAL STUDIES FOR INTRANAS","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250313:nTUA4JLGNN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRZ"],"gpt_icon":0},{"id":"2519833173","title":"Polyrizon Launches Preclinical Studies for Intranasal Naloxone to Combat Opioid Overdose Using Cutting-Edge Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2519833173","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519833173?lang=en_us&edition=fundamental","pubTime":"2025-03-13 19:51","pubTimestamp":1741866660,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250313:nTUA4JLGNN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PLRZ"],"gpt_icon":0},{"id":"2519835539","title":"Polyrizon Launches Preclinical Studies for Intranasal Naloxone to Combat Opioid Overdose Using Cutting-Edge Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2519835539","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519835539?lang=en_us&edition=fundamental","pubTime":"2025-03-13 19:51","pubTimestamp":1741866660,"startTime":"0","endTime":"0","summary":"Raanana, Israel, March 13, 2025  -- Polyrizon Ltd.  , a development stage biotech company specializing in the development of innovative intranasal hydrogels, previously announced the initiation of preclinical studies for intranasal Naloxone, a life-saving opioid overdose treatment.As previously announced, the study will be conducted in collaboration with Professor Fabio Sonvico, Associate Professor at the Department of Food and Drug of the University of Parma  a leading expert in the development of intranasal and pulmonary drug delivery solutions and a member of the Company's Scientific Advisory Board.Polyrizon is a development stage biotech company specializing in the development of innovative medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Polyrizon's proprietary Capture and","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/polyrizon-launches-preclinical-studies-intranasal-115100658.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PLRZ"],"gpt_icon":0},{"id":"2518772335","title":"Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2518772335","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518772335?lang=en_us&edition=fundamental","pubTime":"2025-03-12 04:27","pubTimestamp":1741724820,"startTime":"0","endTime":"0","summary":"Raanana, Israel, March  11, 2025  (GLOBE NEWSWIRE) --  Polyrizon Ltd. (Nasdaq: PLRZ) (the \"Company\" or \"Polyrizon\"), a development stage biotech company specializing in the development of innovative i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/11/3041024/0/en/Polyrizon-Ltd-Files-Annual-Report-on-Form-20-F-for-the-Fiscal-Year-Ended-December-31-2024.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRZ"],"gpt_icon":0},{"id":"2518223720","title":"Polyrizon Initiates Preclinical Studies for Intranasal Naloxone Targeting Opioid Overdose Based on Its Innovative T&T Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2518223720","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518223720?lang=en_us&edition=fundamental","pubTime":"2025-03-10 19:47","pubTimestamp":1741607220,"startTime":"0","endTime":"0","summary":"Raanana, Israel, March 10, 2025  -- Polyrizon Ltd.  , a development stage biotech company specializing in the development of innovative intranasal hydrogels, announced today the initiation of preclinical studies for intranasal Naloxone, a life-saving opioid overdose treatment.The study will be conducted in collaboration with Professor Fabio Sonvico, Associate Professor at the Department of Food and Drug of the University of Parma  a leading expert in the development of intranasal and pulmonary drug delivery solutions and a member of the Company’s Scientific Advisory Board.Polyrizon is a development stage biotech company specializing in the development of innovative medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Polyrizon’s proprietary Capture and Contain TM, or C&C, hydrogel t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/polyrizon-initiates-preclinical-studies-intranasal-114700597.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PLRZ"],"gpt_icon":0},{"id":"2507649876","title":"Polyrizon files divisional patent application with Israel Patent Office","url":"https://stock-news.laohu8.com/highlight/detail?id=2507649876","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507649876?lang=en_us&edition=fundamental","pubTime":"2025-01-30 19:05","pubTimestamp":1738235119,"startTime":"0","endTime":"0","summary":"Polyrizon (PLRZ) announced the filing of a divisional patent application with the Israel Patent Office for its Trap & Target platform technology. T...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/polyrizon-files-divisional-patent-application-with-israel-patent-office?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/polyrizon-files-divisional-patent-application-with-israel-patent-office?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PLRZ"],"gpt_icon":0},{"id":"2507646717","title":"Polyrizon Announces Filing of Divisional Patent Application for Its Innovative Trap & Target™ (T&T) Intranasal Drug Delivery Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2507646717","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507646717?lang=en_us&edition=fundamental","pubTime":"2025-01-30 18:55","pubTimestamp":1738234500,"startTime":"0","endTime":"0","summary":"Raanana, Israel, Jan. 30, 2025  -- Polyrizon Ltd.  , a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced the filing of a divisional patent application with the Israel Patent Office for its Trap & Target (T&T) platform technology. This application focuses exclusively on protecting the Company’s advanced intranasal drug delivery system, which is designed to enhance the effectiveness of medications by increasing their residence time and ensuring close contact with mucosal tissues and aligns with the Company’s recently announced U.S. patent application which encompasses key aspects of Polyrizon’s two core platform technologies: Capture and Contain (C&C), a nasal blocker technology, and Trap and Target (T&T), designed for advanced nasal drug delivery.The T&T platform represents a significant advancement in intranasal drug delivery, offering a novel approach to improving the bioavailability of active pharmaceutical ingredien","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/polyrizon-announces-filing-divisional-patent-105500729.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PLRZ"],"gpt_icon":0},{"id":"2505842091","title":"BRIEF-Polyrizon Commences Gmp Manufacturing Preliminary Process","url":"https://stock-news.laohu8.com/highlight/detail?id=2505842091","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505842091?lang=en_us&edition=fundamental","pubTime":"2025-01-23 19:55","pubTimestamp":1737633304,"startTime":"0","endTime":"0","summary":"BRIEF-Polyrizon Commences Gmp Manufacturing Preliminary ProcessJan 23 (Reuters) - Polyrizon Ltd PLRZ.O:POLYRIZON COMMENCES GMP MANUFACTURING PRELIMINARY PROCESS FOR ITS PL-14 ALLERGY BLOCKER IN PREPAR","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250123:nTUA48GNYT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRZ"],"gpt_icon":0},{"id":"2505209987","title":"Polyrizon Commences Gmp Manufacturing Preliminary Process for Its Pl-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2505209987","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505209987?lang=en_us&edition=fundamental","pubTime":"2025-01-23 19:40","pubTimestamp":1737632400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250123:nTUA48GNYT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PLRZ"],"gpt_icon":0},{"id":"2505173099","title":"Polyrizon Commences GMP Manufacturing Preliminary Process for its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2505173099","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505173099?lang=en_us&edition=fundamental","pubTime":"2025-01-23 19:40","pubTimestamp":1737632400,"startTime":"0","endTime":"0","summary":"Eurofins CDMO Amatsiaquitaine S.A.S., the GMP manufacturer, to support Polyrizon in future commercialization efforts. Raanana, Israel, Jan. 23, 2025  -- Polyrizon Ltd. , a development stage biotech company specializing in the development of innovative intranasal hydrogels, announces today it has commenced preliminary work related to the Good Manufacturing Practice  manufacturing process for its PL-14 allergy blocker in preparation for its planned 2025 clinical trial. The company works closely with Eurofins CDMO, having recently entered into a manufacturing agreement with Eurofins CDMO Amatsiaquitaine S.A.S.Polyrizon is progressing with preparations for its planned 2025 clinical trial. The designated manufacturing facility is equipped to meet the clinical trial material  requirements, ensuring high-quality production and compliance with regulatory standards.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/polyrizon-commences-gmp-manufacturing-preliminary-114000593.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4134","CDMO","BK4123","CTM","PL","PLRZ"],"gpt_icon":0},{"id":"2495509835","title":"BRIEF-Polyrizon Ltd  Files Prospectus Related To Resale By Selling Shareholders Of Up To 2.4 Million Ordinary Shares - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2495509835","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495509835?lang=en_us&edition=fundamental","pubTime":"2024-12-31 06:02","pubTimestamp":1735596121,"startTime":"0","endTime":"0","summary":"BRIEF-Polyrizon Ltd  Files Prospectus Related To Resale By Selling Shareholders Of Up To 2.4 Million Ordinary Shares - SEC FilingDec 30  - Polyrizon Ltd PLRZ.O:POLYRIZON LTD:  FILES PROSPECTUS RELATED TO RESALE BY SELLING SHAREHOLDERS OF UP TO 2.4 MILLION ORDINARY SHARES - SEC FILINGSource text: [ID:n0001213900-24-113515]Further company coverage: PLRZ.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241230:nFWN3NV0C5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRZ"],"gpt_icon":0},{"id":"2495509102","title":"Polyrizon files to sell 2.42M ordinary shares for holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2495509102","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495509102?lang=en_us&edition=fundamental","pubTime":"2024-12-31 06:00","pubTimestamp":1735596010,"startTime":"0","endTime":"0","summary":"16:56 EST Polyrizon (PLRZ) files to sell 2.42M ordinary shares for holders Published first on TheFly – the ultimate source for real-time, market-mo...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/polyrizon-files-to-sell-2-42m-ordinary-shares-for-holders?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/polyrizon-files-to-sell-2-42m-ordinary-shares-for-holders?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PLRZ"],"gpt_icon":0},{"id":"2495054506","title":"Polyrizon Ltd:  Files Prospectus Related to Resale by Selling Shareholders of up to 2.4 Mln Ordinary Shares - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2495054506","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495054506?lang=en_us&edition=fundamental","pubTime":"2024-12-31 05:59","pubTimestamp":1735595976,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241230:nFWN3NV0C5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PLRZ"],"gpt_icon":0},{"id":"2495521153","title":"Polyrizon Shares Rise After Publication of National Patent Application","url":"https://stock-news.laohu8.com/highlight/detail?id=2495521153","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495521153?lang=en_us&edition=fundamental","pubTime":"2024-12-30 23:34","pubTimestamp":1735572840,"startTime":"0","endTime":"0","summary":"Shares of Polyrizon were up 34% to $2.19 after the company said the U.S. Patent and Trademark Office published a national phase patent application by the company.Shares of the Israel-based company, which launched its initial public offering in October, traded as high as $4.80 on Dec. 18.The biotechnology company said the patent application is for two core platform technologies: Capture and Contain, a nasal blocker technology, and Trap and Target, designed for advanced nasal drug delivery.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NHLD","PLRZ"],"gpt_icon":0},{"id":"2495470035","title":"Risk Aversion Grips Wall Street in Penultimate Session of 2024, Fueling Premarket Losses for US Equity Futures","url":"https://stock-news.laohu8.com/highlight/detail?id=2495470035","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495470035?lang=en_us&edition=fundamental","pubTime":"2024-12-30 22:00","pubTimestamp":1735567203,"startTime":"0","endTime":"0","summary":"US equity futures dropped ahead of Monday's opening bell as traders turned risk-averse in the penultimate trading session of 2024.The Dow Jones Industrial Average futures slipped 1%, S&P 500 futures d","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TSYW.SI","QID","BK4215","BK4588","PSQ",".SPX","MNQmain",".IXIC","UDOW","PLRZ","USJW.SI","SDOW","BK4585","SQQQ","TQQQ","USAW.SI","TRAW","EQR","DJX","QLD","BK4007","DOG","NVIW.SI","NQmain","DDM",".DJI","DXD"],"gpt_icon":1},{"id":"2495849542","title":"Polyrizon Files US Patent Application for Nasal Drug Delivery Platforms; Shares Jump Pre-Bell","url":"https://stock-news.laohu8.com/highlight/detail?id=2495849542","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495849542?lang=en_us&edition=fundamental","pubTime":"2024-12-30 21:25","pubTimestamp":1735565123,"startTime":"0","endTime":"0","summary":"Polyrizon  announced Monday the publication of its national phase patent application with the US Patent and Trademark Office.The application covers its core nasal technologies: capture and contain, a blocker system, and trap and target, designed for advanced drug delivery.US patent applications are generally published after 18 months from the date of filing.Shares of the company jumped more than 60% in recent premarket activity.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PLRZ"],"gpt_icon":0},{"id":"2495254983","title":"Top Premarket Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2495254983","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495254983?lang=en_us&edition=fundamental","pubTime":"2024-12-30 20:38","pubTimestamp":1735562291,"startTime":"0","endTime":"0","summary":"Eightco Holdings  shares more than doubled pre-bell Monday following a 3.2% increase in the previous session.Intrusion  shares soared 93% after increasing nearly five-fold on Friday.Polyrizon  shares were up 74% after the company announced a publication by the US Patent States Patent and Trademark Office of a patent application covering hydrogel nasal technologies.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4136","OCTO","PLRZ","BK4097","INTZ"],"gpt_icon":0},{"id":"2495543596","title":"Polyrizon announces publication of patent application for hydrogel nasal tech","url":"https://stock-news.laohu8.com/highlight/detail?id=2495543596","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495543596?lang=en_us&edition=fundamental","pubTime":"2024-12-30 19:35","pubTimestamp":1735558530,"startTime":"0","endTime":"0","summary":"Polyrizon (PLRZ) announced the publication of a national phase patent application by the United States Patent and Trademark Office. The patent appl...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/polyrizon-announces-publication-of-patent-application-for-hydrogel-nasal-tech?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/polyrizon-announces-publication-of-patent-application-for-hydrogel-nasal-tech?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PLRZ"],"gpt_icon":0},{"id":"2492244651","title":"Polyrizon appoints Michal Meir as senior director, regulatory & clinical affairs","url":"https://stock-news.laohu8.com/highlight/detail?id=2492244651","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492244651?lang=en_us&edition=fundamental","pubTime":"2024-12-19 20:30","pubTimestamp":1734611443,"startTime":"0","endTime":"0","summary":"Polyrizon (PLRZ) announced the appointment of Dr. Michal Meir, Senior Consultant at MedTech, as Senior Director of Regulatory and Clinical Affairs....","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/polyrizon-appoints-michal-meir-as-senior-director-regulatory-clinical-affairs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/polyrizon-appoints-michal-meir-as-senior-director-regulatory-clinical-affairs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PLRZ"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":56,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PLRZ\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PLRZ\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PLRZ\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PLRZ\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PLRZ","date":"2025-04-10","current":-1.028385,"percent":0.954545,"low":-29.515607,"twenty":-5.469186,"median":-3.707687,"eighty":-2.661127,"high":-0.939338,"avg":-4.264643,"sd":3.183045,"marketCap":1588855},"quantilePoints":[{"date":"2024-10-31","current":-13.097935,"twenty":-22.948538,"median":-13.097935,"eighty":-12.489816,"marketCap":7858761},{"date":"2024-11-08","current":-3.903419,"twenty":-12.692522,"median":-4.690878,"eighty":-4.316449,"marketCap":3891709},{"date":"2024-11-15","current":-2.661127,"twenty":-9.219549,"median":-4.249136,"eighty":-3.530862,"marketCap":2653144},{"date":"2024-11-22","current":-2.985655,"twenty":-4.737156,"median":-3.736612,"eighty":-3.09924,"marketCap":2976698},{"date":"2024-11-29","current":-3.042447,"twenty":-4.451075,"median":-3.375089,"eighty":-3.037515,"marketCap":3033320},{"date":"2024-12-06","current":-3.212824,"twenty":-4.383762,"median":-3.342636,"eighty":-3.042447,"marketCap":3203186},{"date":"2024-12-13","current":-3.375088,"twenty":-4.191157,"median":-3.358862,"eighty":-3.047315,"marketCap":3364963},{"date":"2024-12-20","current":-7.561496,"twenty":-4.383762,"median":-3.375088,"eighty":-3.07146,"marketCap":7538812},{"date":"2024-12-27","current":-5.744141,"twenty":-5.095085,"median":-3.407542,"eighty":-3.090153,"marketCap":5726909},{"date":"2025-01-03","current":-5.938858,"twenty":-6.101122,"median":-3.569805,"eighty":-3.132991,"marketCap":5921041},{"date":"2025-01-10","current":-4.997727,"twenty":-6.159537,"median":-3.796975,"eighty":-3.146231,"marketCap":4982734},{"date":"2025-01-17","current":-6.142316,"twenty":-6.098128,"median":-3.933764,"eighty":-3.167391,"marketCap":6123889},{"date":"2025-01-24","current":-5.889893,"twenty":-6.192801,"median":-4.333277,"eighty":-3.193353,"marketCap":5872223},{"date":"2025-01-31","current":-5.553327,"twenty":-6.125488,"median":-4.527162,"eighty":-3.214122,"marketCap":5536667},{"date":"2025-02-07","current":-4.552045,"twenty":-6.087615,"median":-4.738105,"eighty":-3.227753,"marketCap":4538389},{"date":"2025-02-14","current":-4.711914,"twenty":-6.064471,"median":-4.705652,"eighty":-3.245278,"marketCap":4697778},{"date":"2025-02-21","current":-4.522596,"twenty":-6.049761,"median":-4.627772,"eighty":-3.258259,"marketCap":4509028},{"date":"2025-02-28","current":-3.707687,"twenty":-6.000655,"median":-4.535397,"eighty":-3.316674,"marketCap":3696564},{"date":"2025-03-07","current":-3.460732,"twenty":-5.929065,"median":-4.501561,"eighty":-3.241954,"marketCap":3450350},{"date":"2025-03-14","current":-1.846098,"twenty":-5.873065,"median":-4.396383,"eighty":-3.213473,"marketCap":2852222},{"date":"2025-03-21","current":-1.508371,"twenty":-5.793429,"median":-4.291207,"eighty":-3.160314,"marketCap":2330433},{"date":"2025-03-28","current":-1.353625,"twenty":-5.705978,"median":-3.977976,"eighty":-3.07146,"marketCap":2091350},{"date":"2025-04-04","current":-0.974631,"twenty":-5.536499,"median":-3.903419,"eighty":-3.030526,"marketCap":1505805},{"date":"2025-04-10","current":-1.028385,"twenty":-5.469186,"median":-3.707687,"eighty":-2.661127,"marketCap":1588855}],"updateTime":1744425287362}}}